Spread the love

A study from thSchool of Life Sciences, Tsinghua University, Beijing 100084, China shows that “Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.”

This study was published in the 7 January issue of 2014 Proc Natl Acad Sci U S A (I.F: >10) by Prof Huang L,   Wang Z  and others from Tsinghua University, Beijing 100084, China.

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMDreports here that: Natural product-based therapy for Mammary Cancer: Celastrol, an antioxidant & anti-inflammatory drug from Thunder of God vine, suppresses Mammary cancer cell migration and invasion via down regulation of Receptor for hyaluronan-mediated motility (RHAMM)/Hyaluronan-mediated motility receptor (HMMR).  This study may suggest that Celastrol, by down regulating its target gene, it may inhibit the expression of RHAMM/HMMR. Together, this study suggests that pharmacological formulations encompassing Celastrol  or its analogues may be used to inhibit cancer metastasis and invasion. 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

CitationBoominathan, Natural product-based therapy for Mammary Cancer: Celastrol, an antioxidant & anti-inflammatory drug from Thunder of God vine suppresses Mammary cancer cell migration and invasion via down regulation of Receptor for hyaluronan-mediated motility (RHAMM)/Hyaluronan-mediated motility receptor (HMMR), 03/October/2014, 10.33 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: This study suggests that Celastrol, by decreasing the expression of RHAMM/HMMR, it may (1) inhibit Mammary cancer cell migration and invasion (MCCMI); and (2) serve as an anti-metastatic agent.


Spread the love